Cargando…
Molecular Epidemiology of Escherichia coli Clinical Isolates from Central Panama
Escherichia coli represents one of the most common causes of community-onset and nosocomial infections. Strains carrying extended spectrum β-lactamases (ESBL) are a serious public health problem. In Central America we have not found studies reporting the molecular epidemiology of E. coli strains imp...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388621/ https://www.ncbi.nlm.nih.gov/pubmed/34438949 http://dx.doi.org/10.3390/antibiotics10080899 |
_version_ | 1783742677670428672 |
---|---|
author | Núñez-Samudio, Virginia Pecchio, Maydelin Pimentel-Peralta, Gumercindo Quintero, Yohana Herrera, Mellissa Landires, Iván |
author_facet | Núñez-Samudio, Virginia Pecchio, Maydelin Pimentel-Peralta, Gumercindo Quintero, Yohana Herrera, Mellissa Landires, Iván |
author_sort | Núñez-Samudio, Virginia |
collection | PubMed |
description | Escherichia coli represents one of the most common causes of community-onset and nosocomial infections. Strains carrying extended spectrum β-lactamases (ESBL) are a serious public health problem. In Central America we have not found studies reporting the molecular epidemiology of E. coli strains implicated in local infections, so we conducted this study to fill that gap. Materials and Methods: We report on an epidemiological study in two reference hospitals from central Panama, identifying the susceptibility profile, associated risk factors, and molecular typing of E. coli strains isolated between November 2018 and November 2019 using Pasteur’s Multilocus Sequence Typing (MLST) scheme. Results: A total of 30 E. coli isolates with antimicrobial resistance were analyzed, 70% of which came from inpatients and 30% from outpatients (p < 0.001). Two-thirds of the samples came from urine cultures. Forty-three percent of the strains were ESBL producers and 77% were resistant to ciprofloxacin. We identified 10 different sequence types (STs) with 30% of the ESBL strains identified as ST43, which corresponds to ST131 of the Achtman MLST scheme—the E. coli pandemic clone. Thirty-eight percent of the E. coli strains with the ESBL phenotype carried CTX-M-15. Conclusions: To the best of our knowledge, this is the first report confirming the presence of the pandemic E. coli clone ST43/ST131 harboring CTX-M-15 in Central American inpatients and outpatients. This E. coli strain is an important antimicrobial-resistant organism of public health concern, with potential challenges to treat infections in Panama and, perhaps, the rest of Central America. |
format | Online Article Text |
id | pubmed-8388621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83886212021-08-27 Molecular Epidemiology of Escherichia coli Clinical Isolates from Central Panama Núñez-Samudio, Virginia Pecchio, Maydelin Pimentel-Peralta, Gumercindo Quintero, Yohana Herrera, Mellissa Landires, Iván Antibiotics (Basel) Article Escherichia coli represents one of the most common causes of community-onset and nosocomial infections. Strains carrying extended spectrum β-lactamases (ESBL) are a serious public health problem. In Central America we have not found studies reporting the molecular epidemiology of E. coli strains implicated in local infections, so we conducted this study to fill that gap. Materials and Methods: We report on an epidemiological study in two reference hospitals from central Panama, identifying the susceptibility profile, associated risk factors, and molecular typing of E. coli strains isolated between November 2018 and November 2019 using Pasteur’s Multilocus Sequence Typing (MLST) scheme. Results: A total of 30 E. coli isolates with antimicrobial resistance were analyzed, 70% of which came from inpatients and 30% from outpatients (p < 0.001). Two-thirds of the samples came from urine cultures. Forty-three percent of the strains were ESBL producers and 77% were resistant to ciprofloxacin. We identified 10 different sequence types (STs) with 30% of the ESBL strains identified as ST43, which corresponds to ST131 of the Achtman MLST scheme—the E. coli pandemic clone. Thirty-eight percent of the E. coli strains with the ESBL phenotype carried CTX-M-15. Conclusions: To the best of our knowledge, this is the first report confirming the presence of the pandemic E. coli clone ST43/ST131 harboring CTX-M-15 in Central American inpatients and outpatients. This E. coli strain is an important antimicrobial-resistant organism of public health concern, with potential challenges to treat infections in Panama and, perhaps, the rest of Central America. MDPI 2021-07-23 /pmc/articles/PMC8388621/ /pubmed/34438949 http://dx.doi.org/10.3390/antibiotics10080899 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Núñez-Samudio, Virginia Pecchio, Maydelin Pimentel-Peralta, Gumercindo Quintero, Yohana Herrera, Mellissa Landires, Iván Molecular Epidemiology of Escherichia coli Clinical Isolates from Central Panama |
title | Molecular Epidemiology of Escherichia coli Clinical Isolates from Central Panama |
title_full | Molecular Epidemiology of Escherichia coli Clinical Isolates from Central Panama |
title_fullStr | Molecular Epidemiology of Escherichia coli Clinical Isolates from Central Panama |
title_full_unstemmed | Molecular Epidemiology of Escherichia coli Clinical Isolates from Central Panama |
title_short | Molecular Epidemiology of Escherichia coli Clinical Isolates from Central Panama |
title_sort | molecular epidemiology of escherichia coli clinical isolates from central panama |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388621/ https://www.ncbi.nlm.nih.gov/pubmed/34438949 http://dx.doi.org/10.3390/antibiotics10080899 |
work_keys_str_mv | AT nunezsamudiovirginia molecularepidemiologyofescherichiacoliclinicalisolatesfromcentralpanama AT pecchiomaydelin molecularepidemiologyofescherichiacoliclinicalisolatesfromcentralpanama AT pimentelperaltagumercindo molecularepidemiologyofescherichiacoliclinicalisolatesfromcentralpanama AT quinteroyohana molecularepidemiologyofescherichiacoliclinicalisolatesfromcentralpanama AT herreramellissa molecularepidemiologyofescherichiacoliclinicalisolatesfromcentralpanama AT landiresivan molecularepidemiologyofescherichiacoliclinicalisolatesfromcentralpanama |